Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 417

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 417
---
 results, which CIBIC then delivers to patients and physicians. For the services provided, the Company sets a price for each category of tests, which CIBIC pays per test requested to Heritas Argentina. CIBIC then sells these tests to end consumers at a price it determines. To a lesser extent, the Company also provides other genetic sequencing services to scientific and health institutions. Revenue generated from selling the tests and other genetics sequencing services is recognized at a point in time when the reports with the results of the tests are sent to CIBIC. Rewell The Rewell division provides an at -homeDNA and microbiome test kits for nutrition -basedhealth risk -managementthat fosters preventive health strategies through DNA and gut microbiome insights. There are two identifiable performance obligations of Rewell: (i) the delivery of the results of the tests to the customer, and (ii) holding a coaching session, with the clients that request it, to review the test results and develop an actionable health plan. The transaction price for Rewell revenue includes the amount of fixed consideration that the Company expects to receive. Revenue generated from the Rewell division is recognized at a point in time when each performance obligation is satisfied. 212

Expenses Sales and marketing, General administrative and Research and development expenses The Company recognizes expenses in the period in which these costs are incurred and are presented by function on the statements of operations. Sales and marketing expenses primarily relate to marketing materials and research that the Company undertakes to increase brand awareness and commercialize its services in the marketplace. Administrative expenses primarily comprise professional fees (mainly related to consultancy, accountancy and legal expenses) and payroll compensation to certain executives. Other operating expenses relate to those that do not depend on general business operations or relate to the other expense categories. Results of Operations Comparison of the Six Months ended December 31, 2024 and the Six months ended December 31, 2023 The following table sets forth the Company’s results of operations for the six months ended December 31, 2024 and 2023:

|                                         |     | For the six months ended 
             December 31, |   |     |            |   |     |  Variation 
      (US$) |   |     | Variation 
       (%) |    |
|                                         |     |                     2024 |   |     |       2023 |   |     |            |   |     |           |    |
|                                         |     |         -in U.S. dollars |   |